Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from SynAct Pharma AB ( (SE:SYNACT) ) is now available.
SynAct Pharma AB held an Extraordinary General Meeting where key resolutions were passed, including the implementation of an employee share option program and authorization for the Board to manage the acquisition and transfer of own shares. These measures aim to secure long-term commitment from employees and enhance the company’s capital structure, potentially increasing shareholder value.
More about SynAct Pharma AB
SynAct Pharma AB is a clinical stage biotechnology company listed on Nasdaq Stockholm, focusing on resolving inflammation through selective activation of the melanocortin system. The company offers a range of oral and injectable selective melanocortin agonists designed to promote anti-inflammatory effects and help patients achieve immune balance.
Average Trading Volume: 177,479
Technical Sentiment Signal: Buy
Current Market Cap: SEK1.13B
See more insights into SYNACT stock on TipRanks’ Stock Analysis page.